cellectis

Cellectis given another shot at off-the-shelf CAR-T

November 8, 2017
Medical Communications, Research and Development CAR-T, biotech, cellectis, drugs, pharma, pharmaceutical

It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both …

doctor_notes

Clinical trials still have a problem with ethnic minorities

November 8, 2017
Medical Communications, Research and Development biotech, clinical trials, drugs, ethnic minorities, pharma, pharmaceutical

Research, published in the Journal of Women’s Health, that aimed to determine the effects of the FDA’s guidance on the …

novartis_outside_1

Novartis’ Kisqali smashes Phase 3 primary endpoint in breast cancer for second time

November 8, 2017
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase …

mosquito

Breathalyser for malaria shows promise in trials

November 7, 2017
Manufacturing and Production, Research and Development biotech, drugs, malaria, pharma, pharmaceutical

Access to sophisticated rapid blood tests for malaria has improved dramatically in recent years but there are still issues in …

roche_dark_0

FDA expands Roche drug indication to approve first-ever treatment for rare blood cancer

November 7, 2017
Manufacturing and Production, Sales and Marketing Cancer, Erdheim-Chester Disease, FDA, Roche, blood cancer, pharma

The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already …

china_block_001_takeda

Takeda’s dengue vaccine surpasses Sanofi’s in P2 trial

November 7, 2017
Manufacturing and Production, Sales and Marketing Sanofi, Takeda, biotech, drugs, pharma, pharmaceutical

Sanofi spent more than $1.5 billion and two decades to develop the first ever vaccine for dengue fever, only a …

addyi-prescription

Valeant backs away from female libido pill

November 7, 2017
Manufacturing and Production, Sales and Marketing Addyi, Valeant, biotech, drugs, pharma, pharmaceutical

Only two years ago, Valeant was so keen to get involved with a pill reported to increase the female libido …

window-2387518_960_720

Clinical trial transparency: Letting the light in

November 6, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, clinical trial transparency, clinical trials, drugs, pharma, pharmaceutical

Transparency is one of those words for which the exact meaning has become clouded by murkier connotations. The chances are …

merckkgaahq

Merck KGaA posts promising osteoarthritis data

November 6, 2017
Research and Development, Sales and Marketing Merck KGaA, biotech, drugs, pharma, pharmaceutical

Merck KGaA’s share price is 7% down over the course of the year – a year that, on the pharmaceutical …

eye_2

Valeant begins long comeback trail with FDA approval

November 6, 2017
Sales and Marketing Valeant, Vyzulta, biotech, drugs, pharma, pharmaceutical

Valeant has had precious little to be happy about over the last few years, it’s bounced from one piece of …

bacteria-1959386_960_720

Gut bacteria may be key to efficacy of immunotherapies

November 6, 2017
Research and Development, Sales and Marketing biotech, drugs, immunotherapy, pharma, pharmaceutical

Why immunotherapies are successful in some individuals and not in others is a matter of huge importance to both patients …

smartphone-1957740_960_720

NHS to offer GP appointments via smartphone

November 6, 2017
Medical Communications, Sales and Marketing GP at hand, NHS, biotech, drugs, pharma, pharmaceutical

It has been announced that I trial will begin in London offering the public GP consultations through their smartphone. The …

novartis_hq_day

Novartis aims for CAR-T double-approval in Europe

November 6, 2017
Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical

Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 3, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing drug, pharma, pharmaceuticals, top ten

As we move into November, we bring you another run down of the top ten most popular articles on Pharmafile.com …

dr-patrick-vallance-gsk

GSK’s R&D head to move on after shift in focus

November 3, 2017
Medical Communications GSK, biotech, drugs, pharma, pharmaceutical

There has been a raft of changes at senior levels of GSK since Emma Walmsley took over the role from …

andrew_witty_gsk_new

Witty to lead way in fast-tracking medicine through UK system

November 3, 2017
Medical Communications AAR, Andrew Witty, GSK, biotech, drugs, pharma, pharmaceutical

The UK government has announced its response to the Accelerated Access Review that was published last year, with former GSK …

gsk_boronia_australia

GSK’s experimental multiple myeloma scores Breakthrough designation with FDA

November 3, 2017
Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, GSK, GlaxoSmithKline, multiple myeloma, pharma

GlaxoSmithKline is celebrating the FDA’s decision to award its experimental therapy GSK2857916 with Breakthrough Therapy Designation as a monotherapy in …

Teva’s woes continue, as shares sink to 17-year low on Q3 results

November 2, 2017
Medical Communications Mylan, Teva, biotech, drugs, pharma, pharmaceutical

Spare a thought for Kare Schultz, he agreed to take on the position of CEO at Teva at the start …

online

Tissue Regenix promotes new CEO from within

November 2, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, tissue regenix

Just over two weeks ago, Tissue Regenix announced that its long-standing CEO, Antony Odell, would be leaving the company. It …

The Gateway to Local Adoption Series

Latest content